Monophosphoryl lipid A (MPL) upregulates major histocompatibility complex (MHC) class I expression by increasing interferon-γ (IFN-γ)

被引:9
作者
Cho, CH
Lee, BK
Kwak, SM
Kim, JD
机构
[1] Inha Univ, Coll Med, Dept Internal Med, Seoul, South Korea
[2] Yonsei Univ, Coll Med, Dept Microbiol, Seoul, South Korea
关键词
monophosphoryl lipid A; MHC class I; IFN-gamma;
D O I
10.3349/ymj.1999.40.1.20
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Tumor immunity is primarily mediated by cells as CD8(+) cytotoxic T lymphocytes (CTL) recognize tumor antigen by MHC class I molecules. But most tumors are associated with a decreased expression of MHC class I to escape the antitumor immunity of the host. Our previous data have demonstrated that MPL has an antitumor effect on metastatic lung cancer of Bib melanoma with enhancing cytotoxicity due to increase of IFN-gamma and IL-2, and decrease of IL-4, which indicates the stimulation of type 1 helper T cells (Th1). To determine the effects of MPL, IFN-gamma , TNF-alpha, and IL-1 alpha on MHC class I expression of B16 melanoma cells, we evaluated the expression of MHC class I molecules with treatments of MPL, IFN-gamma, TNF-alpha, and IL-1 alpha by Row cytometry,The supernatant of MPL-treated spleen cells in vitro upregulated the expression of MHC class I molecules of B16 melanoma cells compared to the control supernatant of spleen cells. The MHC class I expression of B16 melanoma cells treated with IFN-gamma, but not TNF-alpha or IL-1 alpha, increased in a time-dependent manner. In conclusion, MPL upregulated MHC class I expression of B16 melanoma cells by activating spleen sells via IFN-gamma. These data suggest that increased IFN-gamma by MPL is responsible for the upregulation of MHC class I expression to augment cytotoxicity. Therefore, we suggest that MPL could play an important role in immunotherapy.
引用
收藏
页码:20 / 25
页数:6
相关论文
共 27 条
[1]  
ABBAS AK, 1997, CELLULAR MOL IMMUNOL, P249
[2]   Recognition of human renal cell carcinoma and melanoma by HLA-A2-restricted cytotoxic T lymphocytes is mediated by shared peptide epitopes and up-regulated by interferon-gamma [J].
Bernhard, H ;
Maeurer, MJ ;
Jager, E ;
Wolfel, T ;
Schneider, J ;
Karbach, J ;
Seliger, B ;
Huber, C ;
Storkus, WS ;
Lotze, MT ;
zumBuschenfelde, KHM ;
Knuth, A .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1996, 44 (03) :285-292
[3]   HLA MOLECULES IN BASAL-CELL CARCINOMA OF THE SKIN [J].
CABRERA, T ;
GARRIDO, V ;
CONCHA, A ;
MARTIN, J ;
ESQUIVIAS, J ;
OLIVA, MR ;
RUIZCABELLO, F ;
SERRANO, S ;
GARRIDO, F .
IMMUNOBIOLOGY, 1992, 185 (05) :440-452
[4]  
Cho Chul-Ho, 1994, Journal of the Korean Society for Microbiology, V29, P231
[5]  
CONCHA A, 1991, CANCER BIOL, V2, P47
[6]  
EBSEBAN F, 1990, BRIT J CANCER, V62, P1047
[7]   HLA CLASS-I AND CLASS-II EXPRESSION IN RHABDOMYOSARCOMAS [J].
FERNANDEZ, JE ;
CONCHA, A ;
ARANEGA, A ;
RUIZCABELLO, F ;
CABRERA, T ;
GARRIDO, F .
IMMUNOBIOLOGY, 1991, 182 (05) :440-448
[8]   NATURAL-HISTORY OF HLA EXPRESSION DURING TUMOR-DEVELOPMENT [J].
GARRIDO, F ;
CABRERA, T ;
CONCHA, A ;
GLEW, S ;
RUIZCABELLO, F ;
STERN, PL .
IMMUNOLOGY TODAY, 1993, 14 (10) :491-499
[9]   Implications for immunosurveillance of altered HLA class I phenotypes in human tumours [J].
Garrido, F ;
RuizCabello, F ;
Cabrera, T ;
PerezVillar, JJ ;
LopezBotet, M ;
DugganKeen, M ;
Stern, PL .
IMMUNOLOGY TODAY, 1997, 18 (02) :89-95
[10]   HLA class I antigens in human tumors [J].
Garrido, F ;
Cabrera, T ;
LopezNevot, MA ;
RuizCabello, F .
ADVANCES IN CANCER RESEARCH, VOL 67, 1995, 67 :155-195